A single pill could soon spare thousands of children from liver transplants after life-saving gut surgery, turning desperation into hope overnight.
Story Highlights
- WUSTL0717, a gut-specific drug, halts liver fibrosis and boosts nutrient uptake in mice post-intestinal resection.
- Researchers at Washington University revived a shelved pharma compound, patenting it for short bowel syndrome treatment.
- No systemic side effects plague this breakthrough, unlike failed predecessors that caused metabolic chaos.
- Preclinical success promises fewer transplants and better weight gain for vulnerable patients like preterm infants.
- Next tests target IV nutrition stresses, paving the way for human trials.
Short Bowel Syndrome Ravages Lives After Surgery
Small bowel resection surgery saves lives from necrotizing enterocolitis in preterm infants or Crohn’s disease flares. Patients lose massive intestine lengths, triggering short bowel syndrome. Gut bacteria toxins flood the liver, sparking fibrosis and failure. Malnutrition starves bodies, forcing IV nutrition that worsens damage. No drugs exist; transplants loom as the grim endgame. WashU researchers targeted this cycle with precision.
WUSTL0717 Targets Gut-Liver Axis Precisely
WashU chemists synthesized WUSTL0717, a gut-restricted liver X receptor agonist. Mice underwent 50% small bowel resection or sham surgery. Three weeks post-op, researchers dosed orally. The compound stayed in intestines, activating LXR to ramp up HDL cholesterol. HDL neutralized toxins, slashing fibrosis by over 50%. Weight gain surged; nutrient absorption doubled versus controls. Systemic blood levels stayed negligible, dodging hyperlipidemia pitfalls.
Previous LXR drugs boosted HDL liver-wide but tanked metabolism, killing development. This version confines action to the gut, honoring drug design: hit where it hurts, spare the rest. Facts align perfectly; no overreach here.
Team Revives Dormant Compound for Breakthrough
Gwendalyn Randolph, PhD, led the WashU pathology team. Medicinal chemist Bahaa Elgendy, PhD, rebuilt the pharma-shelved molecule. Late pediatric surgeon Brad Warner laid groundwork, proving gut bacteria drive liver doom via LXR paths. Colin A. Martin, MD, brings clinical grit, treating SBS kids daily. Their collaboration—pathology, anesthesiology, surgery—filed patents through WashU’s Office of Technology Management.
Study hit Gastroenterology March 6, 2026. Randolph vows: advance a drug preserving livers, axing transplant needs. Elgendy eyes tissue-specific LXR revolutions. Martin hails it as SBS’s crucial leap. Preclinical only; human trials beckon.
Path from Mice to Medicine Accelerates
Short-term, results greenlight IV nutrition trials, SBS’s real-world hell. Long-term, WUSTL0717 could slash transplant rosters, cut healthcare bills, lift vulnerable lives. Preterm babies, Crohn’s warriors gain absorption, weight, futures. Pharma shifts to gut-smart targeting, reviving LXR for GI woes. Optimism rules sources; preclinical limits temper hype, but data screams promise.
New drug protects liver after intestinal surgery and boosts nutrient absorption
A risky but often lifesaving surgery that removes damaged parts of the small intestine can leave patients facing a new threat: serious liver damage with no available treatment. Now, scientists have…
— The Something Guy 🇿🇦 (@thesomethingguy) March 19, 2026
Stakeholders eye commercialization. Watch for IND filings; success hinges on pediatric scaling. Patients wait, but momentum builds relentlessly.
Sources:
Innovative compound halts common post-intestinal surgery complications
New compound stops common complications after intestinal surgery
New compound shows promise in protecting the liver from damage after small bowel surgery
New Compound Protects Liver After Major Intestinal Surgery
New drug may protect the liver after gut surgery of preterm babies
